MarketPeel
Insider Trading Intelligence
BL

Brendan Luu

ENTA
CHIEF BUSINESS OFFICER · ENANTA PHARMACEUTICALS INC · CIK 0001842369
FILING MIX · LIFETIME57%/43%
BUYS
16
SELLS
12
TOTAL VALUE
$547.6K
COMPANIES
1
ACTIVE SINCE
Jan 2021
HOLDINGS NOW
44,891
AVG SELL PX
$24.06
TRADE KIND
SHOWING 28 / 28
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Brendan Luu, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+50.00%-11.87%-0.58%-11.29%-11.29%
14d2+50.00%-8.04%-1.58%-6.47%-6.47%
30d2+100.00%-17.55%-0.71%-16.84%-16.84%
60d2+100.00%-21.53%-0.05%-21.48%-21.48%
90d2+100.00%-8.07%-3.05%-5.02%-5.02%
180d2+100.00%-14.36%-1.33%-9.80%-9.80%
1y2(1 pending)+0.00%+82.50%+13.53%+68.97%+68.97%
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ENTA · 44,891 shares · as of Feb 12, 2026
022,50045,00067,50090,00020222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 16 buys / 12 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
1,57539,904Feb 12, 2026Feb 13, 2026View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Business Officer
3,257$14.25$46.4K41,634Feb 12, 2026Feb 13, 2026View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
4,98744,891Feb 12, 2026Feb 13, 2026View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Business Officer
1,394$14.23$19.8K38,329Dec 5, 2025Dec 5, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Business Officer
498$14.12$7.0K39,723Dec 1, 2025Dec 3, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
90,00090,000Nov 25, 2025Nov 26, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
7,50043,547Feb 12, 2025Feb 14, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Business Officer
3,326$5.59$18.6K40,221Feb 12, 2025Feb 14, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
2,283$8.06$18.4K36,047Dec 6, 2024Dec 10, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Business Officer
753$8.60$6.5K38,330Dec 1, 2024Dec 3, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
75,00075,000Nov 27, 2024Nov 27, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Business Officer
973$12.41$12.1K39,083Feb 12, 2024Feb 14, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
3,32040,056Feb 12, 2024Feb 14, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Sr. VP, Business Dev.
2,125$9.63$20.5K36,736Dec 5, 2023Dec 6, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Sr. VP, Business Dev.
753$9.49$7.1K38,861Dec 1, 2023Dec 5, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
83,00083,000Nov 22, 2023Nov 22, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
8,94534,670Feb 13, 2023Feb 15, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
11,36046,030Feb 13, 2023Feb 15, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Sr. VP, Business Dev.
6,416$52.77$338.6K39,614Feb 13, 2023Feb 15, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Sr. VP, Business Dev.
498$44.33$22.1K25,725Dec 1, 2022Dec 5, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
40,00040,000Nov 23, 2022Nov 28, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
18,50026,223Nov 23, 2022Nov 28, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Sr. VP, Business Dev.
489$62.49$30.6K7,723Feb 14, 2022Feb 15, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
1,1268,212Feb 14, 2022Feb 15, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
2867,086Feb 14, 2022Feb 15, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
6,8006,800Nov 19, 2021Nov 23, 2021View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
28,40028,400Nov 19, 2021Nov 23, 2021View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
75,00075,000Jan 25, 2021Jan 27, 2021View →
Other insiders · ENTA
Loading peer insiders…
About this filer
CIK 0001842369
ROLE
Chief Business Officer
PRIMARY
ENTA
COMPANIES
1
ACTIVE SINCE
Jan 2021
MARKETPEEL · /INSIDER/0001842369DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback